X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): Vilobelimab
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG. Target enrollment of 18 patients reached across three different dose groups.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
